ERCC6L and breast carcinoma: Moreover, high expression of ERCC6L showed gradually worse outcome in breast cancer (Figure 4G-4I), showing significant difference at stage IV in breast cancer (Figure 4I) and in kidney cancer (Supplementary Figure 6), suggesting that the high expression of ERCC6L is an effective prognostic biomarker in cancers, at least in breast and kidney cancers.